Spero Therapeutics (SPRO) Short-term Investments (2018 - 2022)

Spero Therapeutics (SPRO) has 5 years of Short-term Investments data on file, last reported at $49.9 million in Q1 2022.

• Quarterly Short-term Investments rose 29.04% year-over-year to $49.9 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $49.9 million (up 29.04% YoY) and the FY2021 annual result came in at $33.8 million, down 18.9% from the prior year.
• Short-term Investments climbed to $49.9 million in Q1 2022, from $33.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $90.7 million in Q3 2018 to a low of $2.0 million in Q3 2020.
• A 5-year average of $37.5 million and a median of $33.8 million in 2021 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2020 — Short-term Investments sank 95.85% — and 2021, when it surged 427.37%.
• Tracing SPRO's Short-term Investments over 5 years: stood at $81.4 million in 2018, then slumped by 35.7% to $52.3 million in 2019, then retreated by 20.3% to $41.7 million in 2020, then dropped by 18.9% to $33.8 million in 2021, then jumped by 47.42% to $49.9 million in 2022.
• The last three Short-term Investments figures came in at $49.9 million (Q1 2022), $33.8 million (Q4 2021), and $10.6 million (Q3 2021), per Business Quant data.